RADIOMETER MEDICAL ApS

Company details

CVR number

27509185

Status

Aktiv

Address

Åkandevej 21, 2700, Brønshøj

Legal form

APS

Founded

Jan 14, 2004

Average employees

1,194

Production units

2

Description

Principal activitites When life takes an unexpected turn, Radiometer´s technology and solutions enable caregivers to make informed diagnostic decisions to improve patient care.For health care professionals working with critically ill patients, life is not a given - it is the ultimate goal. Radiometer's goal is to help them.To do this, Radiometer continually seeks deep insights to improve customer experiences. This forms Radiometer's foundation for innovation and enables the Company to continue to provide powerful acute care diagnostic solutions including blood sampling, blood gas analysis, transcutaneous monitoring, immunoassay testing and the related IT management systems and digital services.Radiometer´s lean and agile business model enables the employees located in 42 countries to grow and succeed using the Danaher Business System to construct sustainable processes. Guiding the efforts are four simple, customer-facing priorities: quality, delivery, cost and innovation.The Company develops and produces the products together with the other production companies in the Radiometer Group and distributes the products to customers globally through the sales companies in the Group, through external distributors and to the end-users in Denmark.Special risks The Company monitors the risk factors that may affect the operations and financial results on a regular basis. The identified risks are seeked minimised by operational countermeasures and through insurance. Below is a more detailed description of these factors.Currency risks: The Company's net payments in foreign currencies are usually sold immediately after receipt. There is no hedging of currency risk on foreign currency assets and liabilities.Credit risks: 84% of the Company´s products are sold to sales companies within the Group, where the credit risk is considered limited. 16% of the products are sold to external non-affiliated distributors, who are subject to ongoing credit evaluation. Some of them have a long-time business relationship and therefor the risk is also considered limited for the sales to distributors.Dependence on customers: Revenue is distributed among a large number of markets and a very large number of individual customers, so dependence on individual customers is considered small.Technology development: It is the opinion of the Company that neither in the short- nor medium term will new disruptive technologies appear which would reduce the demand for the product portfolio of the Company on at short notice. Rapid technological developments in artificial intelligence is a risk for the industry and can potentially in the longer term affect demand of products and services, positive and negative, just as it is expected to impact time to market for development of products and solutions.Product liability and business liability: The Company has covered product and business liability risk by an adequate insurance with a premium­ rated insurer.Damage to property and business interruption: Plant and machinery, fixtures and equipment and inventories are insured at replacement value. Significant interruptions of production are covered by a business interruption insurance with a premium-rated insurer.Supplier and material risk: In order to minimize disruption caused by supplier failure, the Company purchases a wide range of components from more than one supplier. For certain critical components inventory is maintained to ensure uninterrupted production in a short time period.

Activities and industry

• Fremstilling af instrumenter og udstyr til måling, afprøvning og navigation
• 265100 — Fremstilling af instrumenter og udstyr til måling, afprøvning og navigation

Latest financial period

Reporting period

2025

Currency

DKK

Revenue

5,860,797,000

Gross profit

2,524,495,000

Operating profit

978,274,000

Profit after tax

851,025,000

Assets

5,804,826,000

Equity

4,304,905,000